A multicenter Phase 2a study published by Pergola et al. found that vadadustat produced better anemia treatment results over placebo in achieving target Hb levels and a significant decrease in SF and hepcidin levels [74]. This evidence concerns the gene GSTM1 and anemia (phenotype).